Quick Heal Technologies Limited has informed the Exchange regarding Outcome of Board Meeting held on May 06, 2025.
QUICKHEAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Quick Heal's Board approved audited consolidated and standalone results for FY25 (year ended March 31, 2025). FY25 revenue fell 4.2% YoY to ₹279.5 Cr, dragged by a weak consumer segment (₹185.7 Cr, -9.2% YoY), while enterprise revenue grew modestly to ₹121.2 Cr (+1.5%). The company slipped into negative territory on profitability with EBITDA of ₹(6.6) Cr versus ₹17.6 Cr last year, and PAT collapsed 79% to ₹5.0 Cr. Q4 FY25 was particularly weak, with revenue down ~19% YoY at ₹65.1 Cr and a loss of ₹(3.3) Cr. Operating cash flow turned negative at ₹(22.3) Cr versus ₹18.2 Cr inflow a year ago, largely due to a ₹38.8 Cr jump in trade receivables. Statutory auditors (MSKA & Associates) issued an unmodified opinion, and Ruchi Bhave was appointed as Secretarial Auditor for five years.
Weak set of numbers – top-line decline, negative EBITDA, sharply lower PAT and negative operating cash flow signal pressure on the business. The stock, already trading near its 52-week low (₹272.50 vs ₹825.90 high), may face further negativity in the near term, though the company highlighted a ₹24+ Cr order book and ₹12+ Cr deferred revenue as forward-looking positives.